景業名邦集團(02231.HK)擬發行1.55億美元新票據
格隆匯 2 月 3日丨景業名邦集團(02231.HK)發佈公吿,交換要約已於2021年2月1日倫敦時間下午四時正屆滿。待交換要約完成後,公司預期將根據交換要約發行1.375億美元新票據。
2021年2月2日,公司及附屬公司擔保人與海通國際、匯豐、東亞銀行有限公司及景匯資本就根據同步新票據發行而發行新票據訂立購買協議。集團擬將同步新票據發行的現金所得款項淨額用於收購或發展物業項目、為現有債務進行再融資及作一般企業用途。
待交換要約及同步新票據發行完成後,公司將於同步新票據發行中發行1750萬美元新票據,並根據交換要約發行1.375億美元新票據,新票據本金總額為1.55億美元。公司將尋求新票據於聯交所上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.